Reed Jobs’s Yosemite raises $350 million second fund to make cancer non-lethal

Yosemite, the cancer-focused venture firm founded by Reed Jobs, closed its second fund at $350 million, well above the $200 million first close in January. The raise signals continued investor appetite for early-stage oncology startups despite a tough venture funding market. Yosemite plans to back companies developing treatments aimed at making cancer a manageable rather than lethal disease. The larger pool gives the firm more capital to support portfolio companies through clinical development. Watch for the firm's first investments from the new fund and whether other specialized biotech vehicles match the pace.